RPG Life Sciences Ltd - Stock Valuation and Financial Performance

BSE: 532983 | NSE: RPGLIFE | Pharmaceuticals & Drugs | Small Cap

RPG Life Sciences Share Price

1,530 57.50 3.90%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on RPG Life Sciences

Overall Rating
Bole Toh

1. Quality

2. Valuation

Overvalued

3. Price Trend

Semi Strong

RPG Life Sciences stock performance -

mw4me loader
P/E Ratio (SA):
29.85
Market Cap:
2,530.8 Cr.
52-wk low:
645.7
52-wk high:
1,740

Is RPG Life Sciences Ltd an attractive stock to invest in?

1. Is RPG Life Sciences Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that RPG Life Sciences Ltd is a average quality company.

2. Is RPG Life Sciences Ltd undervalued or overvalued?

The key valuation ratios of RPG Life Sciences Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is RPG Life Sciences Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of RPG Life Sciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of RPG Life Sciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
RPG Life Sciences Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 6.3%1.6%8.2%13.6%8.3%6.8%17.9%20.2%21.9%24.3%-
Value Creation
Index
-0.6-0.9-0.40.0-0.4-0.50.30.40.60.7-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 236242279294344330376389440513574
Sales YoY Gr.-2.9%15.3%5.1%17.1%-4%13.8%3.6%13.1%16.5%-
Adj EPS 4.20.36.712.886.319.62430.84151.3
YoY Gr.--93.3%2296.4%90%-37.1%-21.7%212.4%22.2%28.5%33%-
BVPS (₹) 76.175.780.888.993.697.1106.8130.9154.7186219
Adj Net
Profit
70.511.121.113.310.432.539.75167.885
Cash Flow from Ops. -5.6-232.87.314.745.850.258.364.890.8-
Debt/CF from Ops. -2.6-16.90.76.13.70.80.2000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 9%8.3%10.9%16.5%
Adj EPS 28.8%38.6%27.8%33%
BVPS10.5%14.7%20.3%20.3%
Share Price 38.5% 43.9% 61.4% 122.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
6.90.48.6158.86.619.320.221.624.125.3
Op. Profit
Mgn %
4.83.589.810.810.51618.219.820.321.5
Net Profit
Mgn %
30.247.23.93.28.610.211.613.214.8
Debt to
Equity
0.10.30.20.30.40.20.1000-
Working Cap
Days
1541501371231261361151181059791
Cash Conv.
Cycle
3652484955554844403055

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 25.30%

Sales growth is growing at healthy rate in last 3 years 10.94%

Net Profit is growing at healthy rate in last 3 years 27.84%

Sales growth is good in last 4 quarters at 15.10%

No data to display

Latest Financials - RPG Life Sciences Ltd.

Standalone Consolidated
TTM EPS (₹) 51.3 5
TTM Sales (₹ Cr.) 574 121
BVPS (₹.) 219 0
Reserves (₹ Cr.) 349 -
P/BV 6.99 0.00
PE 29.85 306.17
From the Market
52 Week Low / High (₹) 645.70 / 1740.00
All Time Low / High (₹) 17.10 / 1740.00
Market Cap (₹ Cr.) 2,531
Equity (₹ Cr.) 13.2
Face Value (₹) 8
Industry PE 48.2

Management X-Ray of RPG Life Sciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of RPG Life Sciences

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales236242279294344330376389440513
Operating Expenses 224234257265307296316318353409
Manufacturing Costs35343830322933405150
Material Costs69778596107104120121128157
Employee Cost 6269747690909195100117
Other Costs 58546064787372627585
Operating Profit 11922293734607187104
Operating Profit Margin (%) 4.7%3.5%8.0%9.8%10.8%10.4%15.9%18.2%19.8%20.2%
Other Income 37210211135
Interest 3324553211
Depreciation 11111011141516161615
Exceptional Items 6400000-5000
Profit Before Tax 6511223201536547392
Tax 12002747142224
Profit After Tax 5311221131129405168
PAT Margin (%) 22.7%0.4%4.2%7.2%3.9%3.3%7.7%10.3%11.7%13.2%
Adjusted EPS (₹)32.30.67.012.78.16.517.524.231.140.9
Dividend Payout Ratio (%)6%132%23%22%30%37%23%30%31%29%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 126125134147155161177216256308
Share Capital 13131313131313131313
Reserves 113112120134142147163203243294
Minority Interest0000000000
Debt1433224048367110
Long Term Debt000161072100
Short Term Debt1432222438295100
Trade Payables37253429522544474665
Others Liabilities 32293321292740384347
Total Liabilities 209212223236284248268303345419

Fixed Assets

Gross Block167176190142151163174180186220
Accumulated Depreciation6171816203551678396
Net Fixed Assets106105109137131128123113104124
CWIP 112291710123125
Investments 00000000058
Inventories38343946544147588395
Trade Receivables36413739683963573337
Cash Equivalents 1112111417057
Others Assets27313511222224222422
Total Assets 209212223236284248268303345419

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity -6-2337154650586591
PBT 6511223201536547392
Adjustment -467137172023171413
Changes in Working Capital -14-611-19-1914-2-4-311
Tax Paid -11-4-2-4-4-4-6-8-19-25
Cash Flow From Investing Activity 59-10-15-30-16-19-11-8-35-106
Capex 57-10-15-55-15-20-11-8-24-33
Net Investments 00000000-12-57
Others 3002500011-16
Cash Flow From Financing Activity -5412-18230-27-39-10-14-17
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -250020-4-90-400
Interest Paid -3-2-2-3-4-4-2-1-10
Dividend Paid -2-3-40-6-5-130-12-16
Others -2318-11614-9-25-5-1-1
Net Cash Flow 0001-1004017-32
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)52.870.88.9814.988.916.8617.2120.3621.824.01
ROCE (%)48.372.58.9715.5812.529.8120.3527.2731.4632.92
Asset Turnover Ratio1.171.21.331.341.331.241.461.471.481.45
PAT to CFO Conversion(x)-0.11-22.750.331.154.181.721.451.271.34
Working Capital Days
Receivable Days64564945565950533423
Inventory Days50524650525243465459
Payable Days222147127119138135106138133128

RPG Life Sciences Ltd Stock News

RPG Life Sciences Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of RPG Life Sciences on 28-Mar-2024 16:01 is ₹1,530.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of RPG Life Sciences stood at ₹2,530.8.
The latest P/E ratio of RPG Life Sciences as of 28-Mar-2024 16:01 is 29.85.
The latest P/B ratio of RPG Life Sciences as of 28-Mar-2024 16:01 is 6.99.
The 52-week high of RPG Life Sciences is ₹1,740 and the 52-week low is ₹645.7.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of RPG Life Sciences is ₹573.5 ( Cr.) .

About RPG Life Sciences Ltd

RPG Life Sciences (RPGLS) is a pharmaceutical organization and was formerly known as Searle (India) Limited. It is a full spectrum world class, customer focussed, innovative pharmaceutical organisation. RPGLS started in 1968 as a joint venture with GD Searle, USA. In 1993, GD Searle withdrew from India and sold its holdings to the RPG Group. The company’s name was changed to RPG Life Sciences Ltd effective April 1, 1999.This company belongs to RPG group

RPGLS was in the business of pharmaceuticals and agrochemicals. It divested the agrochemicals business in the year 2001, as per the strategic decision to focus on pharmaceuticals, fermentation and biotechnology. It develops, manufactures and markets, for national and international markets, a broad range of branded formulations, generics and bulk drugs developed through fermentation and chemical synthesis routes. RPG Life Sciences has research and development facilities that conform to international standards. It has Biotech R&D, API R&D and Formulations R&D. Each of these areas have their respective manufacturing facilities RPGLS employs 750 people. It is a multi-location pharmaceutical manufacturing company with four locations. The manufacturing unit at Thane produces Active Pharmaceuticals Ingredients (also called as bulk drugs) and is ISO 9001 certified and has Therapeutic Goods Administration (TGA), Australia, and approval for three of its major products namely Diphenoxylate Hydrochloride, Haloperidol and Propanthelene Bromide.

The Formulation Plant at Ankleshwar GIDC is ISO 9002 and ISO14001 certified and manufactures pharmaceuticals formulations for domestic as well as for exports. The site also has MHRA (Medicines and Healthcare products Regulatory Agency, UK) approved plant for catering to its global generic business. The second plant at Ankleshwar makes API through the fermentation route to cater to the biotech business.

RPGLS is present in the domestic as well as the international markets. It exports its products primarily to Europe, Latin America, Africa, Australia, CIS Nations and South East Asia.

Major Activities of the Company:

  • Manufacturing and marketing of bulk drugs (synthetic Active Pharmaceutical Ingredients) & formulations internationally [SBU- I],
  • Pharmaceutical formulations & domestic marketing [SBU – II] and Fermentation & biotechnology [SBU – III].

Company’s Patnership:

It is represented in over thirty countries through strategic partnerships and joint ventures.

  • Dossiers/DMF Europe, Canada
  • Artificial Sweetner-UK
  • NSAID-Europe
  •  Formulations - Asia, Canada, Europe.

Achievements:

  • 8 processes patented granted,both in India and overseas
  • First to manufacture Cyclosporin, Daunarubicin, doxorubican and epirubicin in India
  • One of the two manufacturers of Vitamin B12 in India
  • R&D approved  by Department of Science & Technology, Government of India.
  • Only manufacturer of Spironolactone, by the fermentation route, in India.
  • Marketing APIs and formulations catering to all key therapeutic areas across the world.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.